Pliant Therapeutics (PLRX) Projected to Post Earnings on Tuesday

Pliant Therapeutics (NASDAQ:PLRX) is expected to be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.98) per share and revenue of $0.08 million for the quarter.

Pliant Therapeutics Stock Performance

PLRX stock opened at $3.08 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. The stock has a market capitalization of $187.42 million, a price-to-earnings ratio of -0.92 and a beta of 1.03. Pliant Therapeutics has a 1 year low of $2.43 and a 1 year high of $18.00. The stock’s fifty day moving average is $10.37 and its two-hundred day moving average is $12.20.

Insider Buying and Selling

In related news, General Counsel Mike Ouimette sold 13,270 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $11.20, for a total value of $148,624.00. Following the completion of the sale, the general counsel now directly owns 80,774 shares in the company, valued at approximately $904,668.80. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Hans Hull sold 15,936 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $11.20, for a total value of $178,483.20. Following the completion of the sale, the insider now owns 211,558 shares of the company’s stock, valued at approximately $2,369,449.60. This trade represents a 7.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 91,855 shares of company stock valued at $1,026,628. 6.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. cut shares of Pliant Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, February 10th. Citigroup cut shares of Pliant Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $40.00 to $4.00 in a research note on Monday, February 10th. Royal Bank of Canada cut shares of Pliant Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $45.00 to $4.00 in a research note on Monday, February 10th. Oppenheimer restated a “market perform” rating on shares of Pliant Therapeutics in a research note on Monday, February 10th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $4.00 price objective (down from $43.00) on shares of Pliant Therapeutics in a research note on Monday, February 10th. Seven equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $17.75.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.